Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
INJECTION
**Dosage and administration** To be determined by the attending physician. For flushing of in-dwelling cannulae, the usual recommended dose is 10 international units to 50 international units every 4 hours.
INTRAVENOUS
Medical Information
**Indications** **Heparinised Saline Injection** is used for flushing of in-dwelling cannulae and maintaining the patency of intravenous injection devices.
**Contraindications** Heparin is contraindicated in patients who are hypersensitive to the drug. It is contraindicated in patients with haemorrhagic diseases; thrombocytopenia and patients who are haemorrhaging or are at risk of haemorrhage including those with haemophilia, subacute bacterial endocarditis, gastric or duodenal ulcer or severe hypertension. It is also contraindicated in patients who have recently undergone surgery at sites where haemorrhage would be an especial risk.
B01AB51
heparin, combinations
Manufacturer Information
B. Braun Singapore Pte Ltd.
B BRAUN MEDICAL INDUSTRIES SDN BHD
Active Ingredients
Documents
Package Inserts
07 v2_15242561_Heparinised_GIF_A5__SG_150.pdf
Approved: February 7, 2017